南京高科股份有限公司 独立董事高波 2024 年度述职报告 本人作为南京高科股份有限公司（以下简称"公司"）独立董事， 严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立 董事管理办法》等法律法规、规范性文件以及《公司章程》《独立董 事制度》《独立董事年报工作制度》的规定和要求，忠实、诚信、勤 勉尽责地履行独立董事职责和义务，及时关注公司的经营及发展状况， 按时出席 2024 年度召开的各次董事会、股东会及其他相关会议，充 分发挥独立董事的作用，有效地维护公司、全体股东尤其是中小股东 的合法权益。 报告期内，公司董事会进行了换届选举，因任期届满，本人自 2024 年 8 月 11 日起不再继续担任公司独立董事。现将本人 2024 年 任职期间（2024 年 1 月 1 日至 2024 年 8 月 11 日）的主要工作情况 报告如下： 一、个人基本情况 高波，男，1962 年出生，博士，经济学教授。现任南京大学商 学院教授、博士生导师，南京大学城市与不动产研究中心主任，国家 教育部重点研究基地—南京大学长江三角洲经济社会发展研究中心 教授，江苏省三三三人才工程中青年科技领军人才，（中国）消费经 济学 ...

Financial Performance - In 2024, the company achieved a net profit attributable to shareholders of CNY 1,725,229,897.01, an increase of 10.58% compared to CNY 1,560,145,875.01 in 2023[6]. - The company's operating revenue for 2024 was CNY 1,975,445,403.11, representing a decrease of 58.21% from CNY 4,726,511,629.41 in 2023[22]. - The net profit attributable to the parent company was CNY 1,725.23 million, reflecting a year-on-year growth of 10.58%[32]. - The company achieved a basic earnings per share of CNY 0.997 in 2024, representing a 10.53% increase compared to CNY 0.902 in 2023[23]. - The company reported a weighted average return on equity of 9.47%, an increase of 0.29 percentage points from 9.18% in the previous year[23]. - The net profit attributable to the listed company, excluding non-recurring gains and losses, for 2024 is approximately ¥1.62 billion, a decrease of 1.54% compared to ¥1.65 billion in 2023[194]. Cash Flow and Assets - The net cash flow from operating activities was negative CNY 500,820,614.84, an improvement from negative CNY 2,177,480,214.41 in the previous year[22]. - The total assets at the end of 2024 were CNY 38,395,047,667.66, a 2.98% increase from CNY 37,283,181,671.10 at the end of 2023[22]. - The company's asset-liability ratio at the end of the reporting period was 47.97%, with interest-bearing liabilities totaling 9.5 billion yuan, accounting for 24.74% of total assets[36]. - The current ratio improved slightly to 1.17 in 2024 from 1.16 in 2023, while the quick ratio decreased by 5.38% to 0.39[194]. - The debt-to-asset ratio decreased to 47.97% in 2024 from 50.24% in 2023, reflecting a reduction of 4.50%[194]. Dividends and Retained Earnings - The company plans to distribute a cash dividend of CNY 3 per 10 shares, totaling CNY 519,101,893.20, subject to shareholder approval[6]. - The retained earnings available for distribution to shareholders for 2024 amounted to CNY 12,791,290,611.56 after accounting for previous year’s dividends[6]. - The cash dividend for the fiscal year 2023 represents 30.09% of the net profit attributable to ordinary shareholders, which is approximately 1.73 billion RMB[134]. - The cumulative cash dividends over the last three fiscal years amount to approximately 1.73 billion RMB, with an average cash dividend payout ratio of 91.27%[136]. Business Segments and Revenue Sources - The real estate business recorded a contract sales area of 18,700 square meters, a significant decrease of 92.66% year-on-year[33]. - The contract sales amount for the real estate sector was CNY 620.31 million, down 67.59% compared to the previous year[33]. - The municipal business generated revenue of CNY 1,153.73 million, a decrease of 5.67% year-on-year[34]. - The revenue from the pharmaceutical sales segment reached CNY 264,427,648.89, marking a new addition to the company's revenue streams[49]. - The company's main revenue sources for 2024 included real estate development sales, generating approximately ¥197.54 million[200]. Investment and Future Plans - The company plans to gradually exit the real estate business over the next 3-5 years, focusing on high-tech industry investments[35]. - The company invested in three new projects in the high-tech sector, including DiNuoWeiHua and RuiChu Pharmaceutical[35]. - The company aims to strengthen its core business in equity investment and develop the biopharmaceutical industry as a main transformation direction[89]. - The company plans to enhance project sales and cash flow management in its real estate business while gradually exiting real estate development[90]. Risk Management - The company has identified various risks including macroeconomic, business development, investment management, and financial risks in its future outlook[9]. - The company has been actively managing risks for eight consecutive years, with a focus on risk prevention and resolution, particularly in light of macroeconomic conditions and industry trends[96]. - The company’s future plans and strategies are subject to investment risks and do not constitute a commitment to investors[7]. Environmental and Social Responsibility - The company has invested approximately 34.09 million RMB in environmental protection during the reporting period[141]. - The new wastewater treatment plant has a designed processing capacity of 60,000 tons per day, with pollutant discharge limits set at COD ≤ 766.5 tons/year and ammonia nitrogen ≤ 61.32 tons/year, with no exceedances reported during the reporting period[144]. - The company has committed to social responsibility, with a total investment of 8.01 million yuan in public welfare projects, including support for new employment groups[151]. Management and Governance - The total pre-tax remuneration for the board members and senior management during the reporting period amounted to 686.19 million CNY[105]. - The company has established a performance assessment and remuneration management implementation method for the years 2023-2025[113]. - The company has implemented a comprehensive governance structure, enhancing compliance and operational transparency to protect shareholder rights and promote sustainable development[100]. - The company has a diverse management team with backgrounds in finance, engineering, and economics, enhancing its strategic capabilities[106]. Shareholder Information - The total number of common shareholders as of the end of the reporting period is 45,355, an increase from 43,574 at the end of the previous month[171]. - The largest shareholder, Nanjing New Port Development Co., Ltd., holds 601,083,220 shares, representing 34.74% of the total shares, with 229,000,000 shares frozen[173]. - The company has not engaged in any share buybacks during the reporting period[182].

Financial Performance - The company's operating revenue for Q1 2025 reached ¥1,059,709,613.12, a significant increase of 274.89% compared to ¥282,671,547.56 in the same period last year[5] - Net profit attributable to shareholders was ¥692,136,216.19, reflecting a year-on-year growth of 31.62% from ¥525,847,297.99[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥736,255,629.82, up 33.32% from ¥552,258,612.19 in the previous year[5] - The basic earnings per share increased to ¥0.400, a rise of 31.58% compared to ¥0.304 in the same period last year[5] - The weighted average return on equity improved to 3.63%, an increase of 0.68 percentage points from 2.95%[5] - Total operating revenue for Q1 2025 reached ¥1,061,048,907.30, a significant increase from ¥283,631,767.74 in Q1 2024, representing a growth of approximately 274%[21] - Net profit for Q1 2025 was ¥699,858,259.96, compared to ¥525,421,831.66 in Q1 2024, indicating an increase of about 33%[22] - Operating profit for Q1 2025 was ¥702,797,666.62, up from ¥497,869,998.62 in Q1 2024, reflecting a growth of approximately 41%[22] - Total investment income for Q1 2025 was ¥681,930,929.89, compared to ¥588,702,468.93 in Q1 2024, representing an increase of about 16%[22] Cash Flow - The net cash flow from operating activities was ¥43,225,859.51, a significant recovery from a negative cash flow of ¥389,468,188.39 in the same period last year[5] - Cash flow from operating activities for Q1 2025 was ¥43,225,859.51, a turnaround from a negative cash flow of ¥389,468,188.39 in Q1 2024[23] - The company reported a net cash inflow from financing activities of ¥519,777,239.35 in Q1 2025, compared to ¥250,410,416.60 in Q1 2024, indicating a growth of approximately 107%[24] - The net cash flow from financing activities improved to 244,662,010.60 RMB in Q1 2025, compared to -273,252,011.46 RMB in Q1 2024[35] - Total cash inflow from operating activities in Q1 2025 was 291,366,789.11 RMB, up from 199,040,100.55 RMB in Q1 2024, representing an increase of approximately 46.4%[34] - Cash outflow from operating activities increased to 406,558,868.55 RMB in Q1 2025, compared to 180,871,438.98 RMB in Q1 2024, marking an increase of about 124.5%[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥39,308,403,898.07, representing a 2.38% increase from ¥38,395,047,667.66 at the end of the previous year[5] - The company's total current assets as of March 31, 2025, amounted to 17.21 billion yuan, compared to 16.79 billion yuan at the end of 2024[16] - The company's total liabilities as of March 31, 2025, were 18.84 billion yuan, up from 18.42 billion yuan at the end of 2024[18] - The company's total assets increased to CNY 27.12 billion as of March 31, 2025, compared to CNY 26.20 billion at the end of 2024, reflecting a growth of approximately 3.5%[25] - The company's total equity increased to CNY 17.38 billion as of March 31, 2025, compared to CNY 16.99 billion at the end of 2024, reflecting a growth of about 2.3%[27] Sales and Market Activity - The company attributed the revenue growth primarily to increased sales from real estate development projects[7] - In Q1 2025, the company achieved a contract sales area of 42,800 square meters, a year-on-year increase of 6014.29%[12] - The contract sales amount reached 449.30 million yuan, reflecting a year-on-year growth of 1214.79%[12] - The company has not reported any significant new product developments or market expansions during this quarter[5] - The company has no new real estate projects or construction activities in Q1 2025[12] Shareholder Information - The company is actively addressing the remaining frozen shares related to a legal dispute, with 141,193,607 shares still frozen, accounting for 23.49% of its holdings[15] - The company reported a significant increase in accounts receivable, which rose to 974.82 million yuan from 705.08 million yuan[17] - The company’s equity attributable to shareholders increased to 19.29 billion yuan from 18.81 billion yuan[19] Research and Development - Research and development expenses increased to ¥9,297,234.40 in Q1 2025 from ¥2,180,198.29 in Q1 2024, marking a rise of about 326%[21]

南京高科股份有限公司董事会审计委员会 对会计师事务所 2024 年度履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司治理准则》《上海证券交易所上市公司自律监管指引第 1 号—规 范运作》《国有企业、上市公司选聘会计师事务所管理办法》和南京 高科股份有限公司（以下简称"公司"）的《公司章程》《董事会审计 委员会工作细则》等规定和要求，公司董事会审计委员会本着勤勉尽 责的原则，恪尽职守，认真履职。现将对会计师事务所 2024 年度履 职评估及履行监督职责的情况汇报如下： 一、会计师事务所基本情况 （一）基本信息 天衡会计师事务所（特殊普通合伙）（以下简称"天衡"）前身为 1985 年成立的江苏会计师事务所，1999 年脱钩改制，2013 年转制为 特殊普通合伙会计师事务所，于 2013 年 9 月 28 日取得江苏省财政厅 颁发的会计师事务所执业证书，长期从事证券服务业务，是中国首批 获得证券期货相关业务资格和首批取得金融企业审计资格的会计师 事务所之一。 截至 2024 年末，天衡拥有合伙人 85 名、注册会计师 386 名，签 署过证券服务业务审计报告的注册会计师 227 ...

一、资质条件 （一）基本信息 天衡前身为 1985 年成立的江苏会计师事务所，1999 年脱钩改制， 2013 年转制为特殊普通合伙会计师事务所，于 2013 年 9 月 28 日取 得江苏省财政厅颁发的会计师事务所执业证书，长期从事证券服务业 务，是中国首批获得证券期货相关业务资格和首批取得金融企业审计 资格的会计师事务所之一。 截至 2024 年末，天衡拥有合伙人 85 名、注册会计师 386 名，签 署过证券服务业务审计报告的注册会计师 227 名，是国内最具综合实 力的会计师事务所之一。 （二）投资者保护能力 截至 2024 年末，天衡已提取职业风险基金 2,445.10 万元，购买 的职业保险累计赔偿限额为 10,000.00 万元，相关职业保险能够覆盖 因审计失败导致的民事赔偿责任。近三年不存在因执业行为在相关民 事诉讼中承担民事责任的情况。 1 （三）诚信记录 南京高科股份有限公司 2024 年度会计师事务所履职情况评估报告 南京高科股份有限公司（以下简称"公司"）聘请天衡会计师事 务所（特殊普通合伙）（以下简称"天衡"）作为公司 2024 年度财务 报告审计机构、内部控制审计机构。根据财政部、 ...

公司代码：600064 公司简称：南京高科 南京高科股份有限公司 2024年度内部控制评价报告 南京高科股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下 简称"企业内部控制规范体系"），结合本公司（以下简称"公司"）内部控制制度和评价 办法，在内部控制日常监督和专项监督的基础上，我们对公司2024年12月31日（内部控制 评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性， 并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制 进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事会及董事、 监事、高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对 报告内容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息 真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性， 故仅能为实现上述目标提供合理保证。此外，由于情况的变化可能 ...

证券简称：南京高科 证券代码：600064 编号：临 2025-007 号 南京高科股份有限公司 关于计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为客观、真实反映公司资产价值、财务状况及经营情况，根据《企 业会计准则》及公司相关会计政策的规定，基于谨慎性的原则，经减 值测试评估，公司控股子公司南京高科置业有限公司（以下简称"高 科置业"）（公司持股比例为 80%）对紫尧星院项目、迈上品院项目、 紫星荣院一层含底跃房源计提减值准备 63,258 万元，公司控股孙公司 南京高科时代开发有限公司（以下简称"高科时代"）（公司全资子公 司南京高科城市发展有限公司持股比例为 96%）对紫麟景院项目计提 资产减值准备 13,893 万元，合计 77,151 万元。具体情况如下： 一、计提资产减值准备的具体说明 （一）计提资产减值准备相关方法和依据 存货跌价准备计提方法：期末存货按成本与可变现净值孰低原则 计价：年末在对存货进行全面盘点的基础上，对于存货因遭受毁损、 全部或部分陈旧过时或销售价格低于成本等原 ...

2024 年度可持续发展报告 关于本报告 1 董事长致辞 3 关于南京高科 6 目 录 Contents | | | | 公司治理 | 15 | | --- | --- | | 可持续发展治理 | 20 | | 商业道德 | 21 | | 信息安全与隐私保护 | 22 | | 党建引领 | 24 | | 环境合规管理 | 27 | | --- | --- | | 环境合规管理举措 | 30 | | 能源利用与应对气候变化 32 | | | 污染物排放 | 34 | | 废弃物处理 | 39 | | 水资源利用 | 41 | | 循环经济 | 43 | | 生物多样性 | 45 | | 绿色建筑 | 46 | 03 员工 | 治理 | 51 | | --- | --- | | 战略 | 52 | | 影响、风险和机遇管理 52 | | | 合规雇佣 | 53 | | 职业发展 | 53 | | 员工权益 | 55 | | 指标与目标 | 58 | 04 安全与健康 | 治理 | 61 | | --- | --- | | 战略 | 62 | | 影响、风险和机遇管理 63 | | | 指标与目标 | 67 | 0 ...

证券简称：南京高科 证券代码：600064 编号：临 2025-009 号 南京高科股份有限公司 关于为公司部分控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 被担保人名称：南京高科置业有限公司（含控股子公司）、南京高科建设发 展有限公司、南京宁燕置业有限公司、南京科奥置业有限公司。 本次担保金额及已实际为其提供的担保余额： 为保障控股子公司的资金需求，推动公司经营持续稳健发展，根 据控股子公司的实际生产经营情况和发展要求，公司拟为控股子公司 南京高科置业有限公司（以下简称"高科置业"）、全资子公司南京高 科建设发展有限公司（以下简称"高科建设"）提供担保，同时拟授 权高科置业为其下属两家控股子公司提供担保，具体担保情况如下： 本次为南京高科置业有限公司（含控股子公司）、南京高科建设发展有限公 司、南京宁燕置业有限公司、南京科奥置业有限公司提供担保的具体情况如下： | 序 | | 拟提供担 | | 截至目前 | 担保截止日期 | | --- | --- | --- | --- | ...

证券简称：南京高科 证券代码：600064 编号：临 2025-008 号 南京高科股份有限公司 关于与南京银行股份有限公司进行日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 过去 12 个月与同一关联人进行的交易以及与不同关联人进行的交易类别相 关的交易的累计次数与金额：截至公告日，公司向南京银行股份有限公司借款余 额为 3.5 亿元，过去 12 个月，公司向其支付的贷款利息及发行债券相关费用为 1,380.47 万元，其向公司支付的房屋租赁费用为 542.18 万元。 一、关联交易概述 经 2025 年 4 月 21 日公司第十一届董事会第五次会议审议通过， 董事会同意授权董事长按市场化定价原则在 20 亿元额度范围内根据 公司（含公司控股子公司）实际情况与南京银行股份有限公司（以下 简称"南京银行"）进行日常关联交易，主要包括存贷款、发行债券、 房屋租赁等业务。授权有效期（合同签署日）至 2026 年 6 月 30 日。 此项关联交易不构成《上市公司重大资产重组管理办法》规定的 ...